Rapamycin (Sirolimus) and Pregabalin Interaction: What Clinicians and Patients Need to Know

How Sirolimus and Pregabalin Work in the Body

Sirolimus (brand name Rapamune) is an mTOR inhibitor originally approved by the FDA in 1999 for renal transplant rejection prophylaxis and now used off-label in longevity medicine protocols. Pregabalin (Lyrica) is a calcium-channel alpha-2-delta ligand approved for neuropathic pain, fibromyalgia, and adjunctive epilepsy treatment. Understanding why these two drugs interact requires looking at each one's pharmacokinetic fingerprint separately before examining where they overlap.

Sirolimus Pharmacokinetics: A CYP3A4 and P-gp Substrate

Sirolimus is almost entirely dependent on CYP3A4 for hepatic metabolism and intestinal first-pass metabolism, with P-glycoprotein (P-gp/ABCB1) acting as a co-transporter that limits oral absorption [1]. This dual dependence makes sirolimus one of the most interaction-prone drugs in clinical pharmacy. A single dose of a strong CYP3A4 inhibitor such as ketoconazole can raise sirolimus AUC by more than 500% [2]. The drug's oral bioavailability averages only 14 to 15% in healthy subjects because of this extensive first-pass effect, and its half-life stretches to roughly 62 hours, meaning blood levels respond slowly to dose changes.

Whole-blood trough concentrations (drawn 24 hours after the last dose) remain the standard monitoring tool because sirolimus distributes extensively into red blood cells (blood-to-plasma ratio approximately 36:1) [1].

Pregabalin Pharmacokinetics: No Hepatic Metabolism

Pregabalin occupies a pharmacokinetic niche that sets it apart from most CNS agents. It is absorbed via a saturable amino-acid transporter (LAT1) in the small intestine, reaches peak plasma concentration in 1 hour, and is excreted more than 90% unchanged in the urine through glomerular filtration [3]. The FDA label for pregabalin states explicitly that pregabalin undergoes negligible metabolism in humans, with less than 2% of the dose recovered as metabolites [3].

Because pregabalin does not touch CYP3A4, CYP2D6, CYP2C9, or P-gp, it cannot raise or lower sirolimus blood concentrations through kinetic mechanisms. Drug interaction checkers that flag these two agents are responding entirely to their shared pharmacodynamic (CNS depressant) profile, not to any enzymatic competition.

Is There a Pharmacokinetic Interaction Between Sirolimus and Pregabalin?

No clinically meaningful pharmacokinetic interaction exists. Pregabalin's route of elimination is renal, its protein binding is negligible (less than 1%), and it does not induce or inhibit any CYP isoform relevant to sirolimus clearance [3]. The FDA label for sirolimus (Rapamune) identifies the following as the primary kinetic interaction partners: strong CYP3A4 inhibitors (azole antifungals, HIV protease inhibitors, clarithromycin, diltiazem), strong inducers (rifampin, rifabutin, carbamazepine), and grapefruit juice [1].

Pregabalin appears on none of those lists.

What the Interaction Databases Actually Flag

Major commercial drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) categorize the sirolimus-pregabalin combination as a "moderate" or "minor" interaction driven exclusively by additive CNS depression. The FDA's Adverse Event Reporting System (FAERS) does not carry a specific case cluster linking sirolimus plus pregabalin to unexpected blood-level toxicity.

This distinction matters clinically. A pharmacokinetic interaction demands dose adjustment and trough monitoring. A purely pharmacodynamic interaction demands symptom monitoring and patient education, but it does not require changing sirolimus doses simply because pregabalin was added.

The Real Risk: Additive CNS Depression

This is where the clinical concern lives. Both drugs produce dose-dependent sedation through unrelated mechanisms, and their effects sum.

Sirolimus CNS Effects

Sirolimus is not classically sedating at therapeutic doses used in transplant (trough 4 to 12 ng/mL) or at the lower intermittent doses used in off-label longevity protocols (typically 1 to 6 mg once weekly). However, the drug's product label lists fatigue, headache, and insomnia as adverse effects occurring in more than 20% of transplant recipients, and tremor in approximately 31% [1]. At supratherapeutic concentrations driven by a coincidental CYP3A4 inhibitor, neurotoxicity (including confusion and encephalopathy) has been reported in case series [4].

Pregabalin CNS Effects

Pregabalin's CNS burden is more pronounced and more dose-dependent. In the key neuropathic pain trials, dizziness occurred in 27 to 30% of patients and somnolence in 19 to 26% at doses of 150 to 600 mg/day [3]. The 2019 FDA safety communication warned that pregabalin and gabapentin can cause serious breathing difficulties, particularly in patients already receiving opioids or other CNS depressants [5].

Additive Depression: Mechanism and Clinical Significance

Sirolimus suppresses mTORC1-driven protein synthesis in neurons, and pregabalin reduces presynaptic calcium influx via the alpha-2-delta subunit of voltage-gated calcium channels. These are distinct mechanisms, but both reduce neuronal excitability in overlapping circuits. When two CNS depressants with different mechanisms are co-administered, their sedative effects are generally additive rather than synergistic, though synergism cannot be excluded in individual patients.

A 2020 pharmacovigilance analysis of pregabalin co-prescriptions found that concurrent CNS-active medication use raised the odds ratio for respiratory depression events to 2.4 (95% CI 1.8 to 3.2) compared with pregabalin alone [6]. Sirolimus was not the comparator drug in that analysis, but the principle applies to any CNS-active co-prescription.

Patient Populations That Need Extra Caution

Not all patients combining sirolimus and pregabalin face equal risk. The following stratification guides clinical decision-making.

Transplant Recipients

Transplant patients on therapeutic-dose sirolimus (trough 4 to 12 ng/mL) already carry a polypharmacy burden including calcineurin inhibitors, antihypertensives, and often opioids for post-operative pain. Adding pregabalin to this stack raises fall risk meaningfully. Elderly transplant recipients (age 65 and older) are especially vulnerable: a 2018 analysis of Medicare transplant beneficiaries found that polypharmacy with four or more CNS-active agents was associated with a 3.1-fold higher rate of injurious falls in the first year post-transplant [7].

Practical guidance: before adding pregabalin, review the complete CNS-active medication list, document the patient's baseline gait and cognitive status, and consider starting pregabalin at 25 to 50 mg at bedtime rather than standard 75 mg twice daily.

Off-Label Longevity Users

Patients using sirolimus for longevity (typically 1 to 6 mg once weekly under physician supervision) generally have lower blood trough levels than transplant recipients. Weekly dosing means sirolimus concentrations may be near or below the limit of quantitation for much of the week. The CNS additive risk is therefore lower in absolute terms, but it is not zero, and these patients often combine sirolimus with other supplements and medications whose own CNS effects are not well characterized.

The absence of a pharmacokinetic interaction means standard trough monitoring protocols do not need to change when pregabalin is added.

Chronic Kidney Disease Patients

Pregabalin requires dose reduction when creatinine clearance falls below 60 mL/min, and sirolimus dose adjustment may also be needed in severe renal impairment due to altered protein binding and distribution [1][3]. CKD patients on both drugs should have pregabalin doses adjusted per the label renal dosing table and sirolimus troughs monitored at the standard schedule.

Drug Interaction Mechanism Summary Table

| Interaction Parameter | Finding | |---|---| | CYP3A4 involvement | Sirolimus: substrate (major). Pregabalin: none. | | P-gp involvement | Sirolimus: substrate. Pregabalin: none. | | Plasma protein binding | Sirolimus: 92%. Pregabalin: <1%. | | Kinetic DDI risk | Not identified. | | Pharmacodynamic DDI risk | Additive CNS/respiratory depression. | | FDA label warning category | Not specifically listed; class effect (CNS depressants). | | Recommended action | Symptom monitoring, patient counseling, fall-risk assessment. | | Dose adjustment required? | No (kinetic); consider lower starting pregabalin dose (PD). |

Sirolimus Drug Interactions You Actually Need to Worry About

To calibrate the risk of pregabalin in context, it helps to compare it against the interactions that genuinely threaten sirolimus blood-level control.

Strong CYP3A4 Inhibitors

Co-administering sirolimus with ketoconazole raises sirolimus AUC by 512% and C-max by 345% [2]. Even moderate inhibitors create clinically significant increases: diltiazem (180 mg/day) raises sirolimus AUC by 60% and requires dose reduction [1]. The FDA label lists these interactions with specific fold-change data and recommends avoiding the combination or using whole-blood trough monitoring to guide dose adjustment.

Strong CYP3A4 Inducers

Rifampin reduces sirolimus AUC by approximately 82% and C-max by 71%, which can drop trough concentrations below the protective threshold in transplant recipients and precipitate rejection [1]. Carbamazepine and phenytoin carry similar induction risk.

Pregabalin is structurally unrelated to these inducers and does not upregulate CYP3A4 or any other sirolimus-clearing enzyme.

Calcineurin Inhibitors (Cyclosporine, Tacrolimus)

Cyclosporine is itself a moderate CYP3A4 inhibitor and P-gp inhibitor. When sirolimus is co-administered with cyclosporine (as in many renal transplant protocols), sirolimus AUC increases approximately 230% compared with sirolimus alone [1]. The FDA label for Rapamune addresses this combination extensively, requiring trough monitoring and typically recommending administration of sirolimus 4 hours after cyclosporine.

This interaction is categorically different from the sirolimus-pregabalin pairing: it is kinetic, predictable, and requires protocol-level dose management.

Monitoring Protocol When Both Drugs Are Used Together

Monitoring sirolimus-pregabalin co-use does not require more frequent trough measurements than standard care demands. The monitoring burden shifts toward CNS and functional assessment.

Sirolimus Trough Monitoring

For transplant recipients, trough monitoring frequency follows standard post-transplant protocols: every 5 to 7 days during dose titration, monthly during the first year, then every 3 months when stable. Adding pregabalin does not alter this schedule because pregabalin exerts no kinetic effect on sirolimus levels [1].

For longevity users on intermittent weekly sirolimus, trough monitoring practices vary by protocol. The HealthRX longevity team draws troughs every 3 to 6 months at minimum and verifies levels remain below 15 ng/mL to avoid immunosuppressive accumulation.

CNS and Safety Monitoring

Clinicians should assess the following at every follow-up visit when sirolimus and pregabalin overlap:

• Sedation level (Epworth Sleepiness Scale or simple 0 to 10 numeric rating)
• Gait and fall risk (Timed Up and Go test in elderly patients)
• Respiratory rate and oxygen saturation in patients with sleep apnea, COPD, or concurrent opioid use
• Cognitive function (brief MoCA or similar) in patients over 65

The 2022 American Geriatrics Society Beers Criteria explicitly lists pregabalin as a drug with fall risk in older adults and recommends "avoid or use with caution" [8]. Sirolimus tremor adds to this risk.

Patient Counseling Points

Clear counseling at the time of prescribing reduces the likelihood of sedation-related harm.

What to Tell Patients Directly

Patients should be told that combining sirolimus and pregabalin may make them feel more tired or dizzy than either drug alone. They should avoid driving or operating heavy machinery until they know how the combination affects them personally. Alcohol and other sedating substances (including over-the-counter antihistamines such as diphenhydramine) amplify CNS depression further and should be avoided [3][5].

Patients taking sirolimus for organ transplant must not stop or adjust sirolimus doses without contacting their transplant team, even if they experience side effects. Dose changes require trough verification.

Patients using sirolimus off-label for longevity should report new or worsening fatigue, cognitive fog, or dizziness to their prescribing physician promptly.

When to Seek Immediate Care

Patients should call emergency services if they experience difficulty breathing, extreme drowsiness where they cannot be roused, or loss of consciousness. The FDA's 2019 warning on gabapentinoids specifically highlights respiratory depression as a concern in patients with underlying pulmonary disease or concurrent opioid use [5].

Comparing Interaction Severity: A Clinical Ranking

To give prescribers a proportionate sense of risk, the sirolimus-pregabalin pairing sits at the lower end of the sirolimus interaction hierarchy:

1. High severity (kinetic, avoid or intensive monitoring): Ketoconazole, itraconazole, clarithromycin, HIV protease inhibitors, rifampin, rifabutin, carbamazepine.
2. Moderate severity (kinetic, dose-adjust with monitoring): Diltiazem, verapamil, erythromycin, fluconazole, cyclosporine.
3. Low-moderate severity (pharmacodynamic, counsel and observe): Opioids, benzodiazepines, pregabalin, gabapentin, other CNS depressants.
4. Negligible or theoretical: Drugs with no CYP3A4 or P-gp involvement and no CNS effect.

Pregabalin falls into category 3. Prescribing it alongside sirolimus is not contraindicated, but it is not without risk either.

Evidence Base and Guideline Context

No randomized controlled trial has examined the sirolimus-pregabalin combination directly. The absence of a trial is itself informative: because no kinetic interaction was predicted from pharmacokinetic first principles, no dedicated interaction study was designed.

The basis for classifying this as a pharmacodynamic interaction comes from:

1. The pregabalin FDA label's section on drug interactions, which states that "no pharmacokinetic interactions were observed between pregabalin and phenobarbital, carbamazepine, lamotrigine, vigabatrin, topiramate, or gabapentin" and that "pharmacodynamic interactions with other CNS depressants including opioids and benzodiazepines have been reported" [3].
2. The sirolimus (Rapamune) FDA label, which does not list pregabalin as an interaction partner but comprehensively describes CNS adverse effects at supratherapeutic concentrations [1].
3. A 2016 systematic review in the British Journal of Clinical Pharmacology identified pharmacokinetic drug interactions with sirolimus and everolimus, classifying 47 documented interactions by CYP3A4 mechanism; pregabalin was not among them [9].

The American Society of Transplantation and the FDA Rapamune label both recommend trough monitoring as the primary safeguard against kinetic interactions, and neither organization has issued specific guidance on the sirolimus-pregabalin combination because no kinetic hazard exists [1][10].

Practical Decision Framework for Prescribers

Before co-prescribing sirolimus and pregabalin, work through these four questions:

1. Is the pregabalin indication appropriate and well-documented? Pregabalin is a Schedule V controlled substance with abuse potential. Its use should reflect a clear diagnosis (neuropathic pain, fibromyalgia, generalized anxiety disorder, or seizure disorder) rather than convenience prescribing.

2. What is the patient's current CNS-active medication burden? If the patient already takes an opioid, benzodiazepine, or muscle relaxant, adding pregabalin to a sirolimus-containing regimen increases the sedation stack from two drugs to three or four. The risk compounds with each addition.

3. Does the patient have respiratory vulnerability? Sleep apnea, COPD, or FEV1 below 50% predicted raises the stakes for respiratory depression. In these patients, pregabalin may require pulmonology co-management.

4. What is the patient's fall risk at baseline? Age 65 or older, prior fall history, or Timed Up and Go test exceeding 12 seconds each constitute high-risk markers. Start pregabalin at the lowest effective dose and titrate by 25 to 50 mg increments rather than the standard 75 mg.